Cellvizio Needle-Based AQ-Flex™ 19 Confocal Miniprobe™ Enabling Peripheral Lung Nodule Targeting and Imaging Receives 510(k) Clearance

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Mauna Kea Technologies inventor of Cellvizio, the multidisciplinary probe-based and needle-based confocal laser endomicroscopy (pCLE/nCLE) platform, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of the Cellvizio AQ-Flex™ 19 Confocal Miniprobe™ through existing bronchoscopes, transbronchial needles and other bronchoscopic accessories. This marks the 16th U.S. FDA 510(k) clearance of the Cellvizio® p/nCLE platform.

“Our pioneering team has demonstrated that real-time imaging and identification of benign and malignant cellular structures inside pulmonary nodules and lymph nodes with needle-based Confocal Laser Endomicroscopy is not only feasible but highly reproducible.” said Pr. J. T. Annema, M.D., Ph.D., chairman of the Department of Respiratory Medicine, Amsterdam University Medical Centers. “The availability of nCLE inside the lungs has clear potential to have a major impact on the diagnostic accuracy for peripheral nodules, one of the most elusive challenges in the battle against lung cancer.”

Current navigation products provide advanced minimally invasive access to peripheral nodules but with limited ability to achieve direct visualization outside the airways. The Cellvizio AQ-Flex™ 19 Confocal Miniprobe™ can be used through the working channel of existing navigation products to provide direct “through the needle” visualization inside peripheral lesions.

“This is an important regulatory milestone for the Company and, more importantly, we believe this clearance formalizes our market development strategy: to evaluate the potential commercial opportunity for our Cellvizio technology in the interventional pulmonology market,” said Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies. “We believe our Cellvizio AQ-Flex™ 19 Confocal Miniprobe™ unlocks a new era in interventional pulmonology, paving the way toward more precise guidance to identify the optimal area for sampling, and potentially as a real-time feedback technique for diagnostic, staging and treatment procedures in lung lesions.”

Mr. Gershon continued: “We have an established presence in the U.S. GI market, and expect our commercial strategy in the U.S. GI market to be the primary driver of revenue growth in 2019. With more than 240,000 annual lung biopsy procedures in the U.S. alone1, interventional pulmonology represents a compelling market opportunity for Mauna Kea’s next clinical indication for commercial focus. We look forward to sharing our plans to evaluate this opportunity on our 2018 full year results conference call on March 20, 2019.”



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.